Patients with glaucoma or ocular hypertension implanted with SpyGlass Pharma’s Drug Delivery Platform showed a mean 43.7% reduction in intraocular pressure (IOP) at 18 months, compared to baseline, the company reported at the recent Eyecelerator Ophthalmic Innovation Conference in Chicago.
SpyGlass Pharma's IOL-mounted sustained-release drug delivery platform is capable of delivering multiple years of therapy. (Image courtesy SpyGlass Pharma.)
The Spyglass system includes an intraocular lens that contains drug-eluting pads attached to each haptic. It is designed to deliver 3 years of bimatoprost to targeted tissues. Data from the first-in-human study, which involved 23 glaucoma or ocular hypertension patients who were implanted with the lens during cataract surgery, showed that all patients achieved >20% reduction in IOP and remained off topical medications at 18 months. Additionally, 96% of patients achieved IOP levels at or below 18 mmHg. No product-related adverse events were reported.
Patients in the first-in-human study will continue to be followed over time, and Spyglass Pharma reported it will provide longer-term data in 2025. A phase1/2 study (NCT06120842) has enrolled 201 participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery. It will compare the Spyglass system to treatment with timolol maleate ophthalmic solution. GP
